Fluorescein-mediated sonodynamic therapy in a rat glioma model.
Authors: Prada F, Sheybani N, Franzini A, Moore D, Cordeiro D, Sheehan J, Timbie K, Xu Z
Malignant gliomas have a dismal prognosis and significant efforts are being made to develop more effective treatments. Sonodynamic therapy (SDT) is an emerging modality for cancer treatment which combines ultrasound with sonosensitizers to produce a localized cytotoxic effect. The aim of this study is to demonstrate the efficacy of SDT with fluorescein (FL) and low-intensity focused ultrasound in inhibiting the growth of ectopic gliomas implanted in the rat's subcutaneous tissue. In vivo cytotoxicity of FL-SDT was evaluated in C6 rat glioma cells which were inoculated subcutaneously. Tumor specific extracellular FL extravasation and accumulation was assessed with IVIS imaging in rats receiving systemic FL. Effects of FL-SDT with focused low-intensity ultrasound on tumor growth, and histological features of the rat's tumors were investigated. Treatment related apoptosis and necrosis were analyzed using hematoxylin & eosin, and apoptosis-specific staining. IVIS imaging revealed a high degree of FL accumulation within the tumor, with a nearly threefold increase in tumoral epifluorescence signal over background. SDT significantly inhibited outgrowth of ectopic C6 gliomas across all three FUS exposure conditions. TUNEL and active caspase-3 staining did not reveal conclusive trends across control and SDT condition for apoptosis. Our results suggest that SDT with FL and low-intensity FUS is effective in inhibiting the growth of ectopic malignant gliomas in rats. The selective FL extravasation and accumulation in the tumor areas where the blood-brain barrier is damaged suggests the tumor-specificity of the treatment. The possibility to use this treatment in intracranial models and in human gliomas will have to be explored in further studies.
Introduction
Purpose
Other
Study Objective
To evaluate if fluorescein combined with LIFUS produces sonodynamic inhibition of glioma growth in a rat model
Animal model / Human subject
Rat; Sprague-Dawley; age 8 weeks old; sex female
Disease model
glioma
Cargo name and characteristics
Fluorescein (small molecule fluorescent dye used as a sonosensitizer)
Route of administration
intraperitoneal
Outcomes and Safety
Summary of Outcomes
Fluorescein-mediated sonodynamic therapy inhibited glioma growth significantly across all tested exposure conditions, while fluorescein alone and ultrasound alone produced no effect.
Duration of biological effect
7 days
Safety-related matter
No safety-related information or adverse effects are mentioned in the provided text.
Brain Region
Ultrasound Parameters
Ultrasound instrument
SonicConcepts 350 kHz single element device (H-224)
FUS Frequency
350 kHz
FUS Intensity
2-6 W/cm2
FUS Pressure
0.03 Mpa, 0.04 Mpa, 0.055 Mpa
FUS Mode
pulsed
Pulse duration
10 ms
Focal Characteristics
Focal depth: 23 mm; Focal length: 9 mm; Aperture size: 44 mm
Treatment frequency
Single
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search